U.S. markets open in 7 hours 5 minutes

Gemini Therapeutics, Inc. (GMTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.6800-0.0900 (-1.89%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close4.7700
Open4.6400
Bid0.0000 x 800
Ask0.0000 x 1000
Day's Range4.5721 - 4.7400
52 Week Range3.2200 - 19.0850
Volume214,509
Avg. Volume526,939
Market Cap201.752M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.5150
Earnings DateAug 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gemini Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 09/20/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • PR Newswire

    Lightstone Ventures Raises $375 Million Fund

    Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso

  • Business Wire

    Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

    CAMBRIDGE, Mass., September 10, 2021--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation and the presentation of three posters at the 13th International Conference on Complement Therapeutics held in Ioannina, Greece from September 8-13, 2021.

  • Business Wire

    Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual

    CAMBRIDGE, Mass., September 09, 2021--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing Phase 2a study at EURETINA 2021